Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences

被引:54
作者
Maekawa, Keiko
Saeki, Mayumi
Saito, Yoshiro
Ozawa, Shogo
Kurose, Kouichi
Kaniwa, Nahoko
Kawamoto, Manabu
Kamatani, Naoyuki
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shirao, Kuniaki
Shimada, Yasuhiro
Muto, Manabu
Doi, Toshihiko
Ohtsu, Atsushi
Yoshida, Teruhiko
Matsumura, Yasuhiro
Saijo, Nagahiro
Sawada, Jun-ichi
机构
[1] Natl Inst Hlth Sci, Div Biochem & Immunochem, Setagaya Ku, Tokyo 1588501, Japan
[2] Natl Inst Hlth Sci, Project Team Pharmacogenet, Setagaya Ku, Tokyo 1588501, Japan
[3] Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan
[4] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, Tokyo 1588501, Japan
[5] Tokyo Womens Med Univ, Dept Adv Biomed Engn & Sci, Div Genom Med, Tokyo, Japan
[6] Natl Canc Ctr, Natl Canc Ctr, Gastrointestinal Oncol Div, Tokyo, Japan
[7] Natl Canc Ctr Hosp E, Gastrointestinal Oncol Div, Kashiwa, Chiba, Japan
[8] Natl Canc Ctr Hosp E, Div GI Oncol Digest Endoscopy, Kashiwa, Chiba, Japan
[9] Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan
[10] Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Kashiwa, Chiba, Japan
关键词
DPYD; SNP; haplotype; Japanese; 5-fluorouracil;
D O I
10.1007/s10038-007-0186-6
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Dihydropyrimidine dehydrogenase (DPD) is an inactivating and rate-limiting enzyme for 5-fluorouracil (5-FU), and its deficiency is associated with a risk for developing a severe or fatal toxicity to 5-FU. In this study, to search for genetic variations of DPYD encoding DPD in Japanese, the putative promoter region, all exons, and flanking introns of DPYD were sequenced from 341 subjects including cancer patients treated with 5-FU. Fifty-five genetic variations, including 38 novel ones, were found and consisted of 4 in the 5'-flanking region, 21 (5 synonymous and 16 nonsynonymous) in the coding exons, and 30 in the introns. Nine novel nonsynonymous SNPs, 29C > A (Ala10Glu), 325T > A (Tyr109Asn), 451A > G (Asn151Asp), 733A > T (Ile245Phe), 793G > A (Glu265Lys), 1543G > A (Val515Ile), 1572T > G (Phe524Leu), 1666A > C (Ser556Arg), and 2678A > G (Asn893Ser), were found at allele frequencies between 0.15 and 0.88%. Two known nonsynonymous variations reported only in Japanese, 1003G > T (*11, Val335Leu) and 2303C > A (Thr768Lys), were found at allele frequencies of 0.15 and 2.8%, respectively. SNP and haplotype distributions in Japanese were quite different from those reported previously in Caucasians. This study provides fundamental information for pharmacogenetic studies for evaluating the efficacy and toxicity of 5-FU in Japanese and probably East Asians.
引用
收藏
页码:804 / 819
页数:16
相关论文
共 36 条
[1]   ELEVATED URINE, BLOOD AND CEREBROSPINAL-FLUID LEVELS OF URACIL AND THYMINE IN A CHILD WITH DIHYDROTHYMINE DEHYDROGENASE-DEFICIENCY [J].
BAKKEREN, JAJM ;
DEABREU, RA ;
SENGERS, RCA ;
GABREELS, FJM ;
MAAS, JM ;
RENIER, WO .
CLINICA CHIMICA ACTA, 1984, 140 (03) :247-256
[2]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[3]   Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity [J].
Cho, Hyun-Jung ;
Park, Young Suk ;
Kang, Won Ki ;
Kim, Jong-Won ;
Lee, Soo-Youn .
THERAPEUTIC DRUG MONITORING, 2007, 29 (02) :190-196
[4]   Known variant DPYD alleles do not explain DPD deficiency in cancer patients [J].
Collie-Duguid, ESR ;
Etienne, MC ;
Milano, G ;
McLeod, HL .
PHARMACOGENETICS, 2000, 10 (03) :217-223
[5]   Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil - Implications for mechanism of inhibition and electron transfer [J].
Dobritzsch, D ;
Ricagno, S ;
Schneider, G ;
Schnackerz, KD ;
Lindqvist, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (15) :13155-13166
[6]   Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil [J].
Dobritzsch, D ;
Schneider, G ;
Schnackerz, KD ;
Lindqvist, Y .
EMBO JOURNAL, 2001, 20 (04) :650-660
[7]   POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS [J].
ETIENNE, MC ;
LAGRANGE, JL ;
DASSONVILLE, O ;
FLEMING, R ;
THYSS, A ;
RENEE, N ;
SCHNEIDER, M ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2248-2253
[8]  
GREM JL, 1996, CANC CHEMOTHERAPY BI, P149
[9]   Detailed Analysis of Five Mutations in Dihydropyrimidine Dehydrogenase Detected in Cancer Patients With 5-fluorouracil-related Side Effects [J].
Gross, Eva ;
Ullrich, Tobias ;
Seck, Katharina ;
Mueller, Volkmar ;
de Wit, Maike ;
von Schilling, Christoph ;
Meindl, Alfons ;
Schmitt, Manfred ;
Kiechle, Marion .
HUMAN MUTATION, 2003, 22 (06)
[10]  
HEGGIE GD, 1987, CANCER RES, V47, P2203